Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period

Leukemia

Volumn 13, Issue 10, 1999, Pages 1481-1490

  Baudard, M ^a   Beauchamp Nicoud, A ^a   Delmer, A ^a   Rio, B ^a   Blanc, C M ^a   Zittoun, R ^a   Marie, J P ^a  

^a HÔTEL DIEU   (France)

Author keywords

Acute myelogenous leukemia; Prognosis

Indexed keywords

AZACITIDINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0032878617     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401544     Document Type: Article

References (45)

1. Stone RM, Mayer RJ. Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematol Oncol Clin North Am 1993; 7: 47-64.
2. Rees JKH, Gray RG, Wheatley K on behalf of the MRC Leukaemia in Adults Working Party. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. Br J Haematol 1996; 94: 89-98.
3. Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, Sawitsky A, Rosner F, Gussoff B, Silver RT, Karanas A, Cuttner J, Spurr CL, Hayes DM, Blom J, Leone LA, Haurani F, Kyle R, Hutchison JL, Forcier RJ, Moon JH. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968; 32: 507-523.
4. Keating MJ, McCredie KB, Bodey GP, Smith TL, Gehan E, Freireich EJ. Improved prospects for long-term survival in adults with acute myelogenous leukemia. JAMA 1982; 248: 2481-2486.
5. Ghaddar HM, Pierce S, Kantarjian HM, Freireich EJ, Keating MJ, Estey EH. Amsacrine and continuous-infusion high-dose cytostine arabinoside as induction therapy for patients with newly diagnosed acute myelogenous leukemia. Leuk Lymphoma 1996; 22: 71-76.
6. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, Levy P, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchison JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L, Holland JF. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukaemia: a CALGB study. Blood 1982; 60: 454-462.
7. Preisler H, Davis RB, Kirshner J, Dupre E, Richards F, Hoagland HC, Kopel S, Levy RN, Carey R, Schulman P, Gottlieb AJ, McIntyre OR, the Cancer and Leukemia Group B. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. Blood 1987; 69: 1441-1449.
8. Wiernik PH, Banks PLC, Case DC, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313-319.
9. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, McGlave PB, Edlestein M, Harrington DP, O'Connell MJ. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79: 1924-1930.
10. Friedenberg WR, Miller HJ, Marx JJ, Schloesser LL, Reding DJ, Mazza JJ, Hocking WG, Mercier RJ, Raich PC, Cassileth PA. The treatment of older adult patients with acute myeloid leukemia by triple infusion chemotherapy. Am J Clin Oncol 1995; 18: 105-110.
11. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R, Whiteside MG, Kronenberg H, Ma D, Dodds A, Herrmann R, Szer J, Wolf MM, Young GA. Etoposide in acute nonlymphocytic leukemia. Blood 1990; 75: 27-32.
12. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E. Intensive postremission chemotherapy in adults with acute myeloid leukemia. New Engl J Med 1994; 331: 896-903.
13. Hiddemann W, Büchner T. Rationale for high-dose chemotherapy and application of haematopoietic growth factors in acute myeloid leukaemia. Ann Oncol 1995; 6: 27-31.
14. Woods WG, Kobrinsky N, Buckley JD, Lee JW, Sanders J, Neudorf S, Gold S, Barnard DR, DeSwarte J, Dusenbery K, Kalousek D, Arthur DC, Lange BJ. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 1996; 87: 4979-4989.
15. Edenfield WJ, Gore SD. Stage-specific application of allogeneic and autologous marrow transplantation in the management of acute myeloid leukemia. Semin Oncol 1999; 26: 21-34.
16. Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett A, Carella A, Korbling M, Herve P, Maraninchi D, Loẅenberg R, Verdonck LF, de Planque M, Hermans J, Helbig W, Porcellini A, Rizzoli V, Alesandrino EP, Franklin IM, Reiffers J, Colleselli P, Goldman JM. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990; 75: 1606-1614.
17. McMillan AK, Goldstone AH, Linch DC, Gribben JG, Patterson KG, Richards JDM, Franklin I, Boughton BJ, Milligan DW, Leyland M, Hutchison RM, Newland AC. High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia. Blood 1990; 76: 480-488.
18. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Peetermans M, Dardenne M, Vegna ML, Petti MC, Solbu G, Suciu S, for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Engl J Med 1995; 332: 217-223.
19. Burnett AK, Goldstone AH, Stevens RMF, Hann IM, Rees JKH, Gray RG, Wheatley K, for the UK Medical Research Council Adult and Children's Leukaemia Working Parties. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet 1998; 351: 700-708.
20. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710-1717.
21. Fopp M, Fey MF, Bacchi M, Cavalli F, Gmuer J, Jacky E, Schmid L, Tichelli A, Tobler A, Tschopp L, Von Fliedner V, Gratwohl A. Post-remission therapy of adult acute myeloid leukemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1997; 8: 251-257.
22. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. New Engl J Med 1998; 339: 1649-1656.
23. Weick JK, Kopecky TJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Ickers JN, Hynes HE, Welborn JL, Simon SR, Grever M. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1996; 88: 2841-2851.
24. Whitely R, Hannah P, Holmes F. Survival in acute leukemia in elderly patients. No improvement in the 1980s. JAGS 1990; 38: 527-530.
25. Bassan R, Buelli M, Viero P, Minotti C, Barbui T. The management of acute myelogenous leukemia in the elderly: ten-year experience in 118 patients. Hematol Oncol 1992; 10: 251-260.
26. Hutchinson RM, Winfield DA. Mitozantrone and cytosine arabinoside as first line therapy in elderly patients with acute myeloid leukaemia. Br J Haematol 1992; 80: 416-417.
27. The Toronto Leukemia Study Group. Results of chemotherapy for unselected patients with acute myeloblastic leukemia: effect of exclusions on interpretation of results. Lancet 1986; i: 786-788.
28. Wahlin A, Hörnsten P, Jonsson H. Remission rate and survival in acute myeloid leukemia: impact of selection and chemotherapy. Eur J Haematol 1991; 46: 240-247.
29. Baudard M, Marie JP, Cadiou M, Viguie F, Zittoun R. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994; 86: 82-91.
30. Bennett JM, Catovsky D, Daniel MT, Flandrin C, Galton DAG, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985; 103: 620-624.
31. Keating MJ, Cork A, Broach Y, Smith T, Walters RS, McCredie KB, Trujillo J, Freireich EJ. Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leukemia Res 1987; 11: 119-133.
32. Zittoun R, for the EORTC Leukemia Cooperative Group. The EORTC trials for acute myelogenous leukemia. Haematol Cell Ther 1996; 38: 247-252.
33. Fenaux P. Results of APL 91 European trial combining ATRA and chemotherapy: presentation of APL 1993 trial. Leukemia 1994; 8 (Suppl 3): S70-S72.
34. Kaplan EI, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
35. Cox DR. Regression models and life tables. JR Stat Soc B 1972; 34: 187-220.
36. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans retinoic acid in acute promyelocytic leukemia. New Engl J Med 1997; 337: 1021-1028.
37. Brincker H. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat Rep 1985; 69: 5-11.
38. Brito-Babapulle F, Catovsky D, Galton DAG. Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia. Br J Haematol 1987; 66: 445-450.
39. Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, Stein RS, Greer JP, Cooper B, Herzig GP. High dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow up and results. J Clin Oncol 1989; 7: 1260-1267.
40. Arlin Z, Case D, Moore J, Wiernik P, Feldman F, Saletan S, Desai P, Sia L, Cartwright K, the Lederle Cooperative Group. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia. Leukemia 1990; 4: 177-183.
41. Dillman RO, Davis RB, Green MR, Weiss RB, Gottlieb AJ, Caplan S, Kopel S, Preisler H, McIntyre OR, Schiffer C. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia group B. Blood 1991; 78: 2520-2526.
42. Zittoun R, Suciu S, Watson M, Solbu C, Muus P, Mandelli F, Stryckmans P, Peetermans M, Thaler J, Resegotti L, Dardenne M, Willemze R. Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML8A trial. Bone Marrow Transplant 1997; 20: 307-315.
43. Russell JA, Luider J, Weaver M, Brown C, Selinger S, Railton C, Karlsson L, Klessen J. Collection of progenitor cells for allogeneic transplantation from peripheral blood of normal donors. Bone Marrow Transplant 1995; 15: 111-115.
44. + selected cells from peripheral blood. Blood 1997; 89: 3967-3973.
45. Neuss MN, Feussner JR, DeLong ER, Cohen HJ. A quantitative analysis of palliative care decisions in acute nonlymphocytic leukemia. J Am Geriatr Soc 1987; 35: 125-131.